Clinical Trial Update: Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MPDL3280A (atezolizumab) plus CDX-1401 in NY-ESO-1 positive non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CDX-1401
• MPDL3280A (atezolizumab) (atezolizumab)

Snippet

Sponsor: Yale University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN